Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Share News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: HSBC announces redemption of US dollar securities

Thu, 15th Apr 2021 19:37

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

HSBC Holdings PLC - London-based bank - Announces the redemption of its USD2.00 billion 6.875% perpetual subordinated contingent convertible securities. The redemption price will be USD1,000 per USD1,000 of the securities together with any accrued but unpaid interest.

----------

RHI Magnesita NV - Vienna, Austria-headquartered supplier of refractory products - Notes appointment of Non-Executive Director Janet Ashdown as an independent non-executive director of Stolt-Nielsen Ltd, listed on the Oslo Bors.

----------

Blue Star Capital PLC - investment company with a focus on esports, payments, technology and its applications within media and gaming - Says investee Dynasty eSports Pte Ltd achieved its first monthly profit on an operating basis in January. Says Dynasty expects to shortly conclude a round of fundraising in which it is targeting to raise approximately USD5 million. Blue Star retains anti-dilution rights and is considering exercising these rights to participate in Dynasty's fundraising round. Blue Star currently holds approximately 13% of Dynasty.

----------

Alliance Pharma PLC - pharmaceutical company based in Wiltshire - Says Non-Executive Director Nigel Clifford to step down on April 30 after serving for six years.

----------

Futura Medical PLC - Surrey-based pharmaceutical company - Receives conversion notice from HT Riverwood Multi-Growth Fund, managed by Atlantis Investment Management Ltd, for GBP1.5 million loan notes. Says following this there will be no further amounts outstanding to Riverwood. Says following the conversion, Futura will issue 7.5 million shares at a conversion price of 20 pence per share.

----------

CEPS PLC - Bath, England-based investment company focussed on the industrial sector - Says subsidiary Hickton Group Ltd enters a four-year GBP500,000 Coronavirus Business Interruption Loan with Santander UK PLC. Proceeds will be used for general corporate purposes. Says the loan is repayable in 11 consecutive equal quarterly payments starting approximately 12 months after drawdown.

----------

Tavistock Investments PLC - Berkshire-based investment manager - Says holders of 42% of its shares are against possible Team PLC offer. On Wednesday, Tavistock received letters of intent from holders of 25% of shares saying they will reject the possible all-share offer by Team. In addition, Tavistock board members, who own a 16% stake, would not accept an offer at that level from Team as it significantly undervalues the business. On March 23, Jersey-based investment manager Team announced a possible all-share offer for Tavistock worth GBP15.2 million, or 2.5 pence per share. Tavistock's market capitalisation is GBP15.8 million.

----------

Diurnal Group PLC - Cardiff, Wales-based pharmaceutical company focused on hormonal diseases - Withdraws application for maintenance of Europe Efmody orphan designation. Says this follows feedback from the Committee for Orphan Medicinal Products, an advisory committee to the European Medicines Agency. "Diurnal has decided that continuing pursuit of an Orphan Designation for the drug would be likely to cause a significant delay in its European commercial launch. First commercial launch is currently anticipated to be in Q3 2021," says Diurnal.

----------

Emmerson PLC - Khemisset potash project in northern Morocco - Completes phased development plan for Khemisset potash project. Expects "significantly reduced up-front capex" of USD254.6 million. Expects earnings before interest, tax, depreciation and amortisation in first full year of phase four production of USD491.4 million.

----------

CATCo Reinsurance Opportunities Fund Ltd - investor focused on offering returns from investments linked to catastrophe reinsurance risks - Advised of further side pocket investment release amounting to USD19.2 million. Says it is expected to be paid to the company in May, following which the company intends to use it to carry out a seventh compulsory redemption of its shares.

----------

Caerus Mineral Resources PLC - exploration & resource development company focused on minerals in Europe to supply global clean energy drive - Says drilling in Cyprus has begun ahead of schedule. Says Mines Department of Cyprus has accepted its applications for the Kapedes and Vrechia extension licences. Says formal granting of licences expected to take several months but will commence reconnaissance geological mapping and sampling in the interim.

----------

Valeura Energy Inc - Canada-based company engaged in the exploration, development and production of petroleum and natural gas in Turkey - Agrees with TBNG Ltd to amend long stop date for completion of the sale of its shallow conventional gas business for USD15.5 million. Valeura will be entitled to royalty payments over a five-year period, with a minimum royalty payment of USD1.0 million, and maximum of USD2.5 million.

----------

Chesterfield Resources PLC - copper explorer focused on Cyprus - Announces that it has commenced its 2021 mineral exploration campaign in Cyprus. The company is exploring for further copper, gold, zinc and silver, after its successful diamond drill programme of late 2020. Says 15 percussion drill holes are planned during April and May.

----------

By Greg Roxburgh; gregroxburgh@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
10 Jan 2019 11:33

Diurnal Shares Surge As Secures Second Patent For Chronocort In US

LONDON (Alliance News) - Diurnal Group PLC on Thursday said the US Patent & Trademark Office has granted the company a second US patent for Chronocort.Diurnal shares almost tripled on a

Read more
10 Jan 2019 11:26

Diurnal awarded US patent for Chronocort product

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Thursday that the US Patent and Trademark Office (USPTO) has granted a second US patent for its 'Chronocort' modified release hydrocortisone product.

Read more
17 Oct 2018 12:10

Diurnal halts US development of Chronocort after European trials come up short

(Sharecast News) - Speciality pharmaceutical company Diurnal has put all development activities for its modified release hydrocortisone product on hold after it failed to meet its primary endpoint in a recent phase-three European trial.

Read more
17 Oct 2018 10:41

Diurnal Puts All Chronocort US Development Activities On Hold

LONDON (Alliance News) - Diurnal Group PLC said Wednesday it decided to put all US development activities for its Chronocort product on hold, after it failed to meet its primary objective in its a

Read more
8 Oct 2018 17:07

LONDON MARKET CLOSE: Stocks End Lower On Chinese And Italian Woes

LONDON (Alliance News) - Stocks closed lower Monday on the actions of the Chinese and Italian governments, as the pound continued its fall on news from 10 Downing Street there remains "big in of

Read more
8 Oct 2018 15:15

Diurnal Group Child Adrenal Insufficiency Drug Approved In Scotland

LONDON (Alliance News) - Diurnal Group PLC said Monday the Scottish Medicines Consortium approved the routine use of Alkindi, a first-line treatment of young children with adrenal insufficiency to

Read more
8 Oct 2018 12:00

LONDON MARKET MIDDAY: China Prompts Sell-Off In Europe; Insurers Fall

LONDON (Alliance News) - Share prices in London had slipped firmly into the red by midday on Monday following a slump in Chinese equities overnight."Europe is following the Asian lead, with a 3%

Read more
8 Oct 2018 10:33

WINNERS & LOSERS SUMMARY: French Connection In Vogue On Possible Sale

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - up 1.0%. The asset manager confirmed it is in to

Read more
8 Oct 2018 09:29

Diurnal's endocrine drug does not meet trial objective

(Sharecast News) - Clinical trials of Diurnal Group's Chronocort drug failed to meet the primary objective of proving superior to conventional therapy in endocrine control over a 24-hour period.

Read more
8 Oct 2018 08:54

Shares In IP Group, Diurnal Suffer After Chronocort Trial Disappoints

LONDON (Alliance News) - Diurnal Group PLC said Monday its phase-three European trial of Chronocort did not meet its primary objective, causing shares in the pharmaceutical company to property IP

Read more
8 Oct 2018 07:48

LONDON MARKET PRE-OPEN: Lower Call; Schroders Confirms Lloyds Talks

LONDON (Alliance News) - Stocks in London on Monday are set to continue last week's slide, fuelled by concerns that strong US economic data will lead to a quickened pace of interest rate hikes.In

Read more
5 Oct 2018 09:20

Diurnal kicks off adrenal condition trial with first patients

(Sharecast News) - Specialist pharmaceutical company Diurnal said it had enrolled the first two patients in its US-based Chronocort phase III trial for adults with congenital adrenal hyperplasia (CAH).

Read more
5 Oct 2018 08:16

Diurnal Enrols First Patients In Phase Three US Chronocort Trial

LONDON (Alliance News) - Pharmaceutical company Diurnal Group PLC on Friday said the first two patients have been enrolled into its phase three US trial of Chronocort.Chronocort is a form a

Read more
20 Sep 2018 09:56

Diurnal Generates First Revenue But Loss Deepens As Costs Rise

LONDON (Alliance News) - Pharmaceutical firm Diurnal Group PLC said Thursday its annual loss deepened amid higher costs despite generating its first revenue from drug sales.For the year the

Read more
15 Aug 2018 12:39

German Body Says Diurnal Alkindi's Benefit Over Generic Not Proven

LONDON (Alliance News) - Diurnal Group PLC said Wednesday a German body published a study which says that the benefit of the company's product Alkindi over generic hydrocortisone has not been

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.